MaxiVAX SA, a private Swiss biotech company, is conducting a clinical phase 1 trial at the Geneva University Hospitals with its proprietary cancer vaccination MVX-ONCO-1 in 15 patients suffering from various cancers at an advanced stage. The Immuno-Oncology therapeutic protocol and product of MaxiVAX is based on boosting the patient’s own immune response against his/her cancer cells. The first component is a vaccine aiming at an immune protection against existing cancer and metastases. The comp...